PUBLISHER: Grand View Research | PRODUCT CODE: 1678457
PUBLISHER: Grand View Research | PRODUCT CODE: 1678457
The U.S. dry eye syndrome treatment market size is anticipated to reach USD 3.47 billion by 2030 and is anticipated to expand at a CAGR of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. Market growth in the U.S. for dry eye disease (DED) has been significantly influenced by its high prevalence. By 2024, this condition has shown notable age-related increases, particularly among women, with around 6.8% of the adult population diagnosed.
The substantial patient base has highlighted the urgent need for effective treatment options, leading to a burgeoning market for companies catering to this demographic's needs. The aging population, particularly those aged 65 and older, has significantly contributed to the rising incidence of DED. This demographic shift has created increased demand for treatment as pharmaceutical companies and healthcare providers have adapted their strategies.
In 2023 and 2024, heightened awareness of DED, linked to increased screen time from digital devices, has further surged demand. Innovations in treatment options, including prescription medications and over-the-counter (OTC) products, have improved diagnosis rates. By 2025, new therapies such as Reproxalap, IC 265, and Acoltremon are anticipated to enhance relief and drive future market expansion.